Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
26/9 11:40
Novo Nordisk (NYSE: NVO) just made a partnership play worth $600 million with a small biotech called NanoVation that might just change the stock's trajectory for many years to come. On Sept. 18, the pair signed a deal that could eventually pave the way for Novo to make a next-gen...